The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
The company reckons its immunotherapy could improve on Keytruda.
